Loading company…
Paratek develops and sells antibiotics, including NUZYRA® for serious bacterial infections.
Founded in 1996 and based in Boston, Massachusetts, Paratek Pharmaceuticals develops and commercializes antibiotics targeting antimicrobial resistance. Its product NUZYRA® treats conditions including community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. The company raised USD 462 mn in an April 27, 2015 funding round from Gurnet Point Capital and Novo Holdings. In March 2026, Radius Health, Inc. merged with Paratek, with Sixth Street and Blackstone providing USD 1.3 billion in debt financing.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in